Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ANRONASDAQ:HOOKNASDAQ:IMMXNASDAQ:RPTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANROAlto Neuroscience$2.22+0.8%$2.47$1.60▼$17.55$59.56M1.66407,527 shs199,860 shsHOOKHOOKIPA Pharma$1.25-0.4%$1.37$0.72▼$6.77$15.30M0.982,679 shs124,700 shsIMMXImmix Biopharma$2.19+5.8%$2.15$1.26▼$3.00$57.71M0.24153,974 shs141,598 shsRPTXRepare Therapeutics$1.42+2.2%$1.39$0.89▼$4.29$59.62M0.84246,872 shs177,324 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANROAlto Neuroscience+0.36%-11.98%-15.02%+7.67%-80.54%HOOKHOOKIPA Pharma-0.40%-3.85%-20.13%+36.36%-80.11%IMMXImmix Biopharma+5.80%-2.23%-6.01%+32.73%+3.30%RPTXRepare Therapeutics+2.16%0.00%+2.16%+32.71%-57.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANROAlto Neuroscience2.6406 of 5 stars3.32.00.00.02.30.01.3HOOKHOOKIPA Pharma2.9804 of 5 stars3.25.00.00.02.21.70.6IMMXImmix Biopharma3.7629 of 5 stars3.55.00.00.02.73.30.6RPTXRepare Therapeutics2.6496 of 5 stars3.33.00.00.02.02.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANROAlto Neuroscience 2.57Moderate Buy$8.50283.23% UpsideHOOKHOOKIPA Pharma 2.33Hold$4.50260.00% UpsideIMMXImmix Biopharma 3.00Buy$7.00219.63% UpsideRPTXRepare Therapeutics 2.50Moderate Buy$4.50216.90% UpsideCurrent Analyst Ratings BreakdownLatest HOOK, IMMX, ANRO, and RPTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2025ANROAlto NeuroscienceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.006/4/2025IMMXImmix BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.005/15/2025ANROAlto NeuroscienceWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$4.00 ➝ $4.004/7/2025ANROAlto NeuroscienceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.00(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANROAlto NeuroscienceN/AN/AN/AN/A$5.62 per shareN/AHOOKHOOKIPA Pharma$43.95M0.35N/AN/A$4.25 per share0.29IMMXImmix BiopharmaN/AN/AN/AN/A$0.48 per shareN/ARPTXRepare Therapeutics$53.48M1.14N/AN/A$3.56 per share0.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANROAlto Neuroscience-$61.43M-$2.34N/AN/AN/AN/A-39.35%-33.86%8/12/2025 (Estimated)HOOKHOOKIPA Pharma-$43.50M-$5.85N/AN/AN/A-785.66%-120.09%-77.14%8/6/2025 (Estimated)IMMXImmix Biopharma-$21.61M-$0.70N/AN/AN/AN/A-130.02%-86.33%8/11/2025 (Estimated)RPTXRepare Therapeutics-$84.69M-$3.01N/AN/AN/AN/A-78.12%-67.11%N/ALatest HOOK, IMMX, ANRO, and RPTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025HOOKHOOKIPA Pharma-$0.61-$1.23-$0.62-$1.23$3.38 millionN/A5/13/2025Q1 2025ANROAlto Neuroscience-$0.59-$0.53+$0.06-$0.56N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANROAlto NeuroscienceN/AN/AN/AN/AN/AHOOKHOOKIPA PharmaN/AN/AN/AN/AN/AIMMXImmix BiopharmaN/AN/AN/AN/AN/ARPTXRepare TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANROAlto Neuroscience0.1522.5322.53HOOKHOOKIPA PharmaN/A3.613.61IMMXImmix BiopharmaN/A1.801.80RPTXRepare TherapeuticsN/A7.427.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANROAlto NeuroscienceN/AHOOKHOOKIPA Pharma63.88%IMMXImmix Biopharma11.26%RPTXRepare Therapeutics85.09%Insider OwnershipCompanyInsider OwnershipANROAlto NeuroscienceN/AHOOKHOOKIPA Pharma3.30%IMMXImmix Biopharma55.40%RPTXRepare Therapeutics11.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANROAlto NeuroscienceN/A27.07 millionN/AN/AHOOKHOOKIPA Pharma5612.19 million11.79 millionOptionableIMMXImmix Biopharma927.88 million12.43 millionOptionableRPTXRepare Therapeutics18042.89 million37.96 millionOptionableHOOK, IMMX, ANRO, and RPTX HeadlinesRecent News About These CompaniesRepare Therapeutics Inc (RPTX) Stock Forums - Investing.comJune 30 at 11:19 PM | investing.comRepare Therapeutics Out-Licenses Discovery Platforms to DCx Biotherapeutics in Strategic DealJune 25, 2025 | insidermonkey.comRepare Therapeutics Updates Severance Benefits for ExecutivesJune 20, 2025 | tipranks.comRepare Therapeutics (NASDAQ:RPTX) Trading Down 1.3% - What's Next?June 7, 2025 | marketbeat.comRepare Therapeutics Strengthens Leadership with New Executive AppointmentJune 2, 2025 | tipranks.comRepare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial ResultsMay 13, 2025 | financialpost.comFRepare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial ResultsMay 13, 2025 | financialpost.comFRepare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial ResultsMay 13, 2025 | businesswire.comRepare Therapeutics Inc. Common Shares (RPTX)May 2, 2025 | nasdaq.comNewly Launched DCx Biotherapeutics Inks Licensing Deal With Repare TherapeuticsMay 1, 2025 | precisionmedicineonline.comPWhy Repare Therapeutics Inc.’s (RPTX) Stock Is Up 5.60%April 29, 2025 | aaii.comACathie Wood’s ARK ETF focuses on GitLab stock, sheds Repare TherapeuticsApril 15, 2025 | investing.comRepare Therapeutics CEO Lloyd Segal resigns, Steve Forte succeedsApril 1, 2025 | markets.businessinsider.comLifeSci Capital Reaffirms Their Hold Rating on Repare Therapeutics (RPTX)April 1, 2025 | markets.businessinsider.comRepare Therapeutics Names Forte as President, CEOMarch 31, 2025 | marketwatch.comRepare Therapeutics Announces Leadership TransitionsMarch 31, 2025 | businesswire.comWhat Makes Repare Therapeutics (RPTX) a New Buy StockMarch 11, 2025 | zacks.comRepare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 7, 2025 | businesswire.comRepare Therapeutics price target lowered to $5 from $10 at H.C. WainwrightMarch 7, 2025 | markets.businessinsider.comHere's Why We're Watching Repare Therapeutics' (NASDAQ:RPTX) Cash Burn SituationMarch 4, 2025 | uk.finance.yahoo.comRepare Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues LagMarch 4, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHOOK, IMMX, ANRO, and RPTX Company DescriptionsAlto Neuroscience NYSE:ANRO$2.22 +0.02 (+0.82%) Closing price 07/1/2025 03:59 PM EasternExtended Trading$2.22 +0.00 (+0.09%) As of 04:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.HOOKIPA Pharma NASDAQ:HOOK$1.25 -0.01 (-0.40%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$1.25 +0.00 (+0.40%) As of 07/1/2025 05:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.Immix Biopharma NASDAQ:IMMX$2.19 +0.12 (+5.80%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$2.20 +0.01 (+0.46%) As of 07/1/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.Repare Therapeutics NASDAQ:RPTX$1.42 +0.03 (+2.16%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$1.42 +0.01 (+0.35%) As of 04:37 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
